Launch of KIPRES Tablets 5mg
April 18, 2008
KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd. (Headquarter: Tokyo, President: Ikuo Ogihara) launched today "Kipres® Tablets 5mg" (INN: montelukast sodium), a leukotriene receptor antagonist / bronchial asthma and allergic rhinitis treatment drug, which was already approved on January 25, 2008.
Montelukast sodium has been developed by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. KYORIN Pharmaceutical has been contributing to the asthma treatment through marketing products containing montelukast sodium, "Kipres® Tablets 10mg" for adults and "Kipres® Chewable Tablets 5mg" for pediatric patients aged 6 years and older, since August 2001, and "Kipres® Oral Granules 4mg" for pediatric patients aged 1 year and older but under 6 years since October 2007. In addition, the company has obtained a marketing approval of allergic rhinitis in adults for "Kipres® Tablets 10mg" in January 2008.
Treatment by the daily single dose (bed time) of "Kipres® Tablets 5mg" has demonstrated its efficacy and safety profiles comparable to those of "Kipres® Tablets 10mg" in adult allergic rhinitis and improved three major symptoms of allergic rhinitis; stuffy nose, runny nose and sneezing. This product has approval for the treatment of bronchial asthma in adults while approved dose (dosage for bronchial asthma in adults is 10mg).
KYORIN Pharmaceutical has been pursuing Franchise Customers Strategy under which the company has been concentrating its marketing resources on the fields of respiratory, ear nose throat (ENT) and urology. The company will continue to make efforts to further contribute to asthma and allergic rhinitis treatments through aiming to immediately penetrate Kipres into the markets of respiratory and ENT.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.